BioPorto A/S

BioPorto A/S is a Danish biotechnology company primarily engaged in the development and commercial sale of diagnostic tests. The firm's flagship product is the NGAL Test, a novel biomarker used for the early detection of acute kidney injury, a condition that is often difficult to diagnose in its early stages with traditional methods. The company places a strong emphasis on innovation, actively expanding its product portfolio to include other cutting-edge diagnostic solutions targeting various medical conditions. BioPorto caters to hospitals and clinical research facilities, contributing significantly to the advancement of patient care through more timely and accurate diagnostic capabilities. Founded in 1992 and headquartered in Copenhagen, BioPorto is a pivotal player in the biomedical landscape, addressing critical gaps in the diagnostic market and fostering improvements in global healthcare outcomes. Its activities play a substantial role in the medical diagnostics sector, impacting research and clinical practices with reliable and validated technologies.